Stereotaxis (STXS)
:STXS
Want to see STXS full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.Company Guidance
Major Regulatory Approvals
Received multiple recent regulatory approvals including 4 U.S. FDA approvals in recent months (PMA for MAGIC in January; FDA clearance for Synchrony last month), plus approvals in Europe and China. Genesys X previously received FDA clearance. These approvals create a new foundational ecosystem of products and materially expand the company's addressable market.
Launch and Early Clinical Success of MAGIC Catheter
MAGIC (proprietary therapeutic ablation catheter) received PMA and has been used in first procedures at multiple U.S. hospitals with reported successful outcomes (including treating complex congenital heart disease patients who failed manual catheters). Early demand exceeds supply.
Disposable (Razor-Blade) Revenue Potential
Initial U.S. MAGIC procedures show disposable revenue often >$8,000 per procedure and always >$5,000 per procedure. Example order in Europe: $100,000 in disposables from a single hospital for approximately one month's procedures. Company expects production to reach ~500 catheters per month by year-end, which management says would produce disposable revenue that meaningfully exceeds current recurring revenue.
New Digital and Capital Products
FDA clearance for Synchrony (digital surgery cockpit) with initial orders and shipments; management is confident in $3 million revenue from Synchrony in 2026. Genesys X robot (installable without construction in existing cath labs) has a healthy pipeline and a plan to establish at least 5 active Genesis programs this year.
Strategic Acquisition and Long-Term Vision
Acquisition of Robocath announced, adding a complementary robotic mechanism of action for endovascular device navigation and strengthening a vision for remote, automated robotic treatment for stroke and cardiovascular disease.
Reiterated Revenue Guidance and Quarterly Ramp Expectation
Management reiterated guidance for double-digit revenue growth in 2026 with annual revenue expected to surpass $40 million and sequential quarterly growth; expects both Q3 and Q4 to exceed $10 million each.
Gross Margin and Adjusted Operating Expense Discipline
Reported gross margin of 60% (recurring gross margin 66%; system gross margin 39%). Adjusted operating expenses (excluding noncash charges) were $6.7 million in Q1, essentially flat vs. prior-year adjusted OpEx of $6.8 million, reflecting cost discipline while investing in the transition.
Balance Sheet and Financing Actions
Cash and cash equivalents of $14.6 million and no debt at March 31. Management utilized an ATM opportunistically at higher-than-current valuation to strengthen the balance sheet and bridge through the Robocath acquisition and ramp period; company is pursuing nondilutive/nondebt financing options.
STXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $1.92 | $1.85 | -3.65% |
Mar 09, 2026 | $2.07 | $1.97 | -4.83% |
Nov 11, 2025 | $2.85 | $2.43 | -14.74% |
Aug 07, 2025 | $2.19 | $2.50 | +14.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Stereotaxis (STXS) report earnings?
Stereotaxis (STXS) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Stereotaxis (STXS) earnings time?
Stereotaxis (STXS) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STXS EPS forecast?
STXS EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.